A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
ABSTRACT Transplantation of deceased donor allografts presents significant challenges, including HLA matching restrictions and the associated risks of ischemia-reperfusion injury (IRI), precipitating long-term allograft dysfunction and graft loss. Here, we propose a novel, universal, cell-based immunotherapy using chimeric antigen receptor (CAR) Tregs targeted against intercellular adhesion molecule (ICAM-)1, a critical anchor protein in inflamed microenvironments upregulated in IRI and alloimmunity. By engineering Tregs with ICAM-1-specificity, including constructs coexpressing IL-10 to support a suppressive Treg phenotype, we will study the stability and immunosuppressive qualities of the engineered Treg products. Additionally, we propose methods for investigating the efficacy of these CAR Tregs in mitigating IRI in a murine heterotopic heart transplant model. The innovative line of studies described here seeks to (1) realize a targeted, HLA-independent CAR Treg therapy for transplant recipients and (2) address delayed graft function and long-term graft loss by offering an alternative to current chemical immunosuppressants that lack specificity and require lifelong treatment.
Grant Summary
A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $727K for university, nonprofit, healthcare org. Applications are due 2031-07-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $727K
2031-07-31
- 1Confirm your organization is eligible for A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity: Frequently Asked Questions
Who is eligible for the A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity?
A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity provide?
A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity provides up to $727K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity deadline?
Applications for A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity are due 2031-07-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity?
To apply for A novel universal Treg therapy via ICAM-1 specific chimeric antigen receptor to suppress ischemia reperfusion injury and alloimmunity, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.